| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Wahl Bryan serves as a General Counsel at TARS. Across recent SEC filings that breaks down to 0 buys and 17 sells. Those positions are worth an estimated $4.3M at current prices.
Historically, Wahl Bryan's trades have earned a below-average insider score of 43/100 across 14 rated trades. Over a 12-month horizon, 21.4% of those trades were profitable, with an average 12-month return of -60.4%.
The biggest single holding is TARS (~$4.3M) as General Counsel. The recent filings there lean toward selling, a net 40,530 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sell | 12,440 | $68.36 | $850,417.03 | -16.3% | -6.3% | - | |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sell | 9,686 | $47.88 | $463,765.53 | -15.8% | -17.7% | +29.3% | |
| Mar 18, 2024 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sale+OE | 4,436 | $30.60 | $135,741.60 | -9.8% | -5.8% | +50.8% | |
| Nov 30, 2023 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sale+OE | 8,356 | $16.31 | $136,286.36 | -20.7% | +129.1% | +217.3% | |
| Mar 23, 2023 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sell | 1,078 | $12.55 | $13,531.63 | -6.2% | +51.2% | +176.9% | |
| Mar 20, 2023 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sell | 696 | $12.94 | $9,003.69 | -3.8% | +46.1% | +141.5% | |
| Mar 16, 2023 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sale+OE | 337 | $13.43 | $4,525.91 | -1.8% | +38.5% | +135.3% | |
| Dec 2, 2022 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sell | 1,154 | $16.90 | $19,502.60 | -7.8% | -10.5% | -8.8% | |
| Dec 1, 2022 | TARS Tarsus Pharmaceuticals, Inc. | General Counsel | Sale+OE | 2,347 | $16.62 | $39,016.50 | -13.6% | -9.3% | -6.2% |